Letter: In the Matter of the Application of Northern States Power Company d/b/a Xcel Energy for Authority to Increase Rates for Electric Service in Minnesota
August 28, 2026 — AELP's letter urges the Minnesota Public Utilities Commission (MN PUC) to reverse its decision letting Xcel raise its authorized return on equity (ROE) from 9.25% to 9.6%.
Break Up Big Medicine: An Agenda to Restore Power Over the U.S. Health Care System to Patients and Practitioners While Saving Families More Than $6,000 a Year
August 27, 2026 — The Break Up Big Medicine agenda offers reforms that would wrest control over our health care system from Big Medicine, whose fiduciary duty is to investors, and restore it to patients and the practitioners who have sworn an oath to care for them.
Minding the Gaps in Surveillance Pricing Reform
August 25, 2026 — This memo aims to build upon a prior analysis, showing the most common problematic carveouts for surveillance pricing legislation. The goal is to help lawmakers and regulators anticipate and avoid such loopholes, which risk neutering a prohibition and allowing surveillance pricing legislation to become a permission slip rather than a restriction on ubiquitous price discrimination. Below are some of the most common loopholes that weaken and derail reform.
Model Legislation: Open Real Estate Listings Act
August 20, 2026 — This model legislation closes the loopholes, puts a stop to so-called "private listings" except in narrow circumstances, and it requires that homes be open to viewing by anyone interested, regardless of who represents them.
Emma Freer’s Testimony at Public Hearing on Atrium Health and WakeMed
August 17, 2026 — Emma Freer testifies in Wake County, North Carolina on Atrium's proposed takeover of WakeMed
Ban Prior Authorization: Ending Big Medicine’s Strategy to Boost Profits by Denying Medically Necessary Care
August 6, 2026 — This policy brief first traces how prior authorization evolved into today’s pervasive corporate care veto, explains the attendant harms, and describes the shortcomings of recent reform efforts. It then proposes a federal ban on prior authorization, prohibiting Big Medicine conglomerates with a financial conflict of interest from both imposing prior authorization requirements and adjudicating requests for coverage.